|

|
Nutrilib.com
A comprihensive source of nutritional information
|
|
BOX WARNING Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of imipramine pamoate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Imipramine pamoate is not approved for use in pediatric patients ( see WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use ).
| | |
TOFRANIL-PM SUMMARY
Tofranil-PM® (imipramine pamoate capsules), is a tricyclic antidepressant, available as capsules for oral administration. The 75-, 100-, 125-, and 150-mg capsules contain imipramine pamoate equivalent to 75, 100, 125, and 150 mg of imipramine hydrochloride.
Tofranil-PM (imipramine) is indicated for the following:
For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.
|
TOFRANIL-PM NEWS HIGHLIGHTS Media Articles Related to Tofranil-PM (Imipramine)
Depression leads to internal fat in 70-somethings (AP) Source: Y! Health Depression News [2008.12.01]
Cognitive Behavioural Therapy (CBT) 'Works Best With Recurrent Depression' Source: Depression News From Medical News Today [2008.11.30]
Treating depression seen important in heart failure (Reuters) Source: Y! Health Depression News [2008.11.28]
Depression May Up Heart Attack Risk Source: MedicineNet Congestive Heart Failure Specialty [2008.11.26]
Seniors Who Experienced The Great Depression Facing Growing Anxiety Today Source: Anxiety / Stress News From Medical News Today [2008.11.25]
Published Studies Related to Tofranil-PM (Imipramine)
Treatment of Panic Disorder with Agoraphobia: Randomized Placebo-Controlled Trial of Four Psychosocial Treatments Combined with Imipramine or Placebo. [2008.06.13]
Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. [2008.02]
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. [2008.01]
Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. [2008]
The effects of imipramine on P50 suppression, prepulse inhibition and habituation of the startle response in humans. [2007.12]
Clinical Trials Related to Tofranil-PM (Imipramine)
The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial [Recruiting]
Dichotic Listening as a Predictor of Medication Response in Depression [Recruiting]
Treatment of Depression Following Multiple Brain Tests [Recruiting]
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
|
TOFRANIL-PM PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Tofranil-PM has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Tofranil-PM review by 31 year old female patient | | | Rating |
| Overall rating: | |           |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | | Treatment Info |
| Condition / reason: | | panic attacks |
| Dosage & duration: | | 25mg taken 1 daily for the period of 3 years |
| Other conditions: | | tachycardia |
| Other drugs taken: | | propranolol | | | Reported Results |
| Benefits: | | After 2-3 weeks complete abatement of panic attack symptoms. After one year tried to stop taking them but within 3 weeks symptoms were back. continued for two more years and stopped taking them. Have not had any symptoms for @10 years now |
| Side effects: | | hyperactivity for up to 8 hrs after taking. |
| Comments: | | started at 5 mg then increased every 5-7 days up to 25 mg. Hyperactivity decreased with longer treatment |
|
|
|
Page last updated: 2008-12-01
|
|
-- advertisement --
|